• Publications
  • Influence
Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis*
The guanine nucleotide-binding protein Ras exists in solution in two different conformational states when complexed with different GTP analogs such as GppNHp or GppCH2p. State 1 has only a very lowExpand
  • 108
  • 13
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
ABSTRACT Background: To compare the pharmacokinetics of Sandoz biosimilar adalimumab (GP2017) with reference adalimumab (Humira) in healthy volunteers (PK similarity study) and to compare theExpand
  • 6
  • 1
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
AIMS To assess pharmacokinetics (PK) and safety of GP2015, a proposed etanercept biosimilar, in two studies: comparison with etanercept originator (ETN, bioequivalence study) and comparison of GP2015Expand
  • 22
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the
Objectives To demonstrate the equivalent efficacy and compare the safety and immunogenicity of an etanercept biosimilar, GP2015, with reference etanercept (ETN) in patients with moderate-to-severe,Expand
  • 11
THU0145 Pharmacokinetics and Safety of GP2015, A Proposed Etanercept Biosimilar, and Etanercept Originator Product in Healthy Male Subjects: A Randomised Two-Way Crossover Study
Background GP2015 is a proposed etanercept (tumor necrosis factor inhibitor) biosimilar. Objectives To compare the pharmacokinetics (PK) and safety of GP2015 and etanercept originator productExpand
  • 8
AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®
Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis. Biosimilars are approved biologics with comparable quality, safety andExpand
  • 2
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
OBJECTIVES This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with referenceExpand